SP-1-303
Solid Tumors (ER+)
PreclinicalCandidate Lead
Key Facts
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage biotech focused on enhancing radiation therapy (RT) for cancer through novel small molecule therapies. Its mission is to increase cure rates and improve quality of life by developing targeted radiation sensitizers and protective agents. The company's strategy leverages a dual-platform approach of halogenated pyrimidines and selective HDAC inhibitors, with a lead Phase II candidate, Ropidoxuridine, in glioblastoma. Shuttle is advancing its pipeline through strategic academic collaborations and recently announced initiatives in AI for scientific workflows.
View full company profile